Advertisement

Introduction to part two of a three-part theme on hereditary bleeding disorders

Published:October 30, 2018DOI:https://doi.org/10.1016/j.transci.2018.10.008
      It has been a great pleasure for me to work with these authors and read their papers. I again wish to thank Dr. Gail Rock for this opportunity. I also wish to thank Drs Donna di Michele of the NIH and Dr. Jayson Stoffman from the University of Manitoba for advice and assistance in editing. I also wish to thank the staff at Elsevier for all their support. As the diagnosis of Factor XIII deficiency remains problematic, I invited Dr. Alisa Wolberg to review this topic. Dr. Wolberg is a basic discovery science researcher with interests in fundamental mechanisms of hemostasis and thrombosis. Her particular focus is on clot formation, structure, and stability. In her laboratory, she examines mechanisms that influence clot quality, including thrombin generation, fibrinogen and Factor XIII. Dr. Wolberg discussed this with Dr. Bryce Kerlin. Dr. Kerlin is a pediatric hematologist-oncologist and a physician scientist in Columbus, Ohio. He is affiliated with Nationwide Children's Hospital, and his interests include the basic and translational aspects of pediatric thrombosis, coagulation protease crosstalk with glomerular biology, and factor XIII deficiency. Specific to factor XIII deficiency, he has been involved in the clinical development of novel therapeutic approaches (plasma derived FXIII and recombinantXIIIa). Mike Durda is a first-year medical student at Ohio State University and a board certified Medical Laboratory Scientist with an interest in clinical laboratory hemostasis. He is also the recipient of a North American Society of Thrombosis and Hemostasis, NASTH Summer Fellowship to work on the development of a novel factor XIII activity assay in Dr. Bryce Kerlin’s laboratory. Collectively, their paper is entitled State of the Art in Factor XIII Laboratory Assessment emerged from their common interests in factor XIII biology and biochemistry, and the clinical laboratory challenges in assessing factor XIII levels and function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect